Concept of reaction volume in the in vivo ligand-receptor model

Journal of Nuclear Medicine

Volumn 37, Issue 1, 1996, Pages 118-125

  Delforge, Jacques ^a   Syrota, André ^a   Bendriem, Bernard ^a  

^a SERVICE HOSPITALIER FRÉDÉRIC JOLIOT   (France)

Author keywords

compartmental model; distribution volume; lipophilicity; PET; reaction volume; receptors

Indexed keywords

ARTICLE; BINDING AFFINITY; COMPARTMENT MODEL; HYPOTHESIS; LIGAND BINDING; LIPOPHILICITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR BINDING;

ANIMALS; HUMANS; LIGANDS; MODELS, BIOLOGICAL; RECEPTORS, CELL SURFACE; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030009751     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (46)

1. Mintun MA, Raichle ME, Kilbourn MR, Wooten GF, Welch MJ. A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography. Ann Neurol 1984;15:217-227.
2. Syrota A. Paillotin G, Davy JM, Aumont MC. Kinetics of in vivo binding of antagonist to muscarinic cholinergic receptor in the human heart studied by positron emission tomography. Life Sci 1984;35:937-945.
3. Vera DR, Krohn KA, Scheibe PO, Stadalnik RC. Identifiability analysis of an in vivo receptor-binding radiopharmacokinetic system. IEEE Trans Biomed Eng 1985;32:312-322.
4. Perlmutter JS, Larson KB, Raichle ME, et al. Strategies for in vivo measurement of receptor binding using positron emission tomography. J Cereb Blood Flow Metab 1986;6 154-169.
5. Wong DK, Gjedde A, Wagner HN. Quantification of neuroreceptors in the living human brain I. Irreversible binding of ligands. J Cereb Blood Flow Metab 1986,6: 137-146.
6. 11C]Flumazenil kinetics in human brain using the multi-injection approach. J Cereb Blood Flow Metab 1993;13:S791.
7. Delforge J, Le Guludec D, Syrota A, et al. Quantitation of myocardial muscarinic receptors with PET in humans. J Nucl Med 1993,34:981-991.
8. Delforge J, Syrota A, Mazoyer BM Identifiability analysis and parameter identification of an in vivo ligand-receptor model from PET data. IEEE Trans Biomed Eng 1990;37:653-662.
9. 11C]Flumazeml kinetics for the estimation of ligand transport rate and receptor distribution using positron emission tomography J Cereb Blood Flow Metab 1991; 11:735-744.
10. Huang SH, Barrio JB, Phelps ME. Neuroreceptor assay with positron emission tomography, equilibrium versus dynamic approaches. J Cereb Blood Flow Metab 1986;6:515-521.
11. Gjedde A, Wang DF. Modeling neuroreceptor binding of radioligands in vivo. In: Frost JJ, Wagner HN, eds. Quantitative imaging: neuroreceptors, neurotransmitters and enzymes Raven Press, New York, 1990;51-79.
12. Wong DK, Gjedde A, Wagner HN, et al. Quantification of neuroreceptors in the living human brain. II Inhibition studies of receptor density and affinity. J Cereb Blood Flow Metab 1986;6.147-153.
13. 76Br]bromolisuride binding to dopamine D2 receptors studied by PET. J Cereb Blood Flaw Metab 1991;11.914-925.
14. Syrota A. PET: evaluation of cardiac receptors. In. Marcus ML, Skorton HR, Schelbert HR, Wolf GL, eds, Braunwald E, consulting ed. Cardiac imaging - principles and practice a companion of Braunwald's heart disease Philadelphia: W.B. Saunders: 1990,1256-1270.
15. 18F]Cyclofoxy and PET J Cereb Blood Flow Metab 1993;13:24-42
16. Walker JL. Intracellular inorganic ions in cardiac tissue In: Fozzard H, Haber E, Jennings R, Katz AM, Morgan HE, eds The heart and cardiovascular system, scientific foundations. Raven Press; New York, 1986;561-572
17. Delforge J, Jamer M, Syrota A, et al. Noninvasive quantification of muscarinic receptors in vivo with positron emission tomography in the dog heart. Circulation 1990;82:1494-1504.
18. Syrota A, Comar D, Paillotin G, et al Muscarinic cholinergic receptor in the human heart evidenced under physiological conditions by positron emission tomography. Proc Natl Acad Sci USA 1985;82:584-588.
19. Le Guludec D, Delforge J, Desruennes M, et al. Changes in myocardial muscarinic receptors after human cardiac transplantation: a PET study. Circulation 1991;86:1-256.
20. Le Guludec D, Delforge J, Syrota A, Desruennes M, Valette H, Gandjbakhch I. Merlet P. In vivo quantification of myocardial muscarinic receptors in heart transplant patients. Circulation 1994,90:172-178.
21. 11]C-Flumazenil and a single-experiment protocol J Cereb Blood Flow Metab 1995,15 254-300.
22. Delforge J, Syrota A, Lancon LP, et al. Cardiac beta-adrenergic receptor density measured in vivo using PET, CGP 12177 and a new graphical method. J Nucl Med 1991,32:739-748.
23. Selikson M, Gibson RE, Eckelman WC, Reba RC Calculation of binding isotherms when ligand and receptor are in different volumes of distribution. Analytical Biochem 1980,108:64-71.
24. Vera DR, Scheibe FO, Krohn KA, Trudeau W, Stadalnik R. Goodness-of-fit and local identifiability analysis of a receptor-binding radiopharmacokinetic system IEEE Trans Biomed Eng 1992;39:356-367
25. Farde L, Hall H, Ehrin E, Sedvall G. Quantitative analysis of D2 dopamine receptor binding in the living brain by PET. Science 1986;231:258-261.
26. Moerlein SM, Laufer P, Stocklin G. Effect of lipophilicity on the in vivo localization of radiolabelled spiperone analogues. Int J Nucl Med Biol 1985;12:353-356.
27. Stocklin G. Radioligands for PET studies of D2 receptors butyrophenone and ergot derivatives. In: Baron JC, Comar D, Farde L, Martinot JL, Mazoyer B, eds. Brain dopaminergic systems: imaging with positron tomography. 1991;5-22.
28. Kessler RM, Ansari MS, de Paulis T, et al. High affinity dopamine D2 receptor radioligands. Regional rat brain distribution of iodinated benzamides. J Nucl Med 1991;32 1593-1600.
29. Frost JJ, Wagner HN Kinetics of binding to opiate receptors in vivo predicted from in vitro parameters. Brain Research 1984;305;1-11.
30. Seeman P, Niznik HB, Guan HC Elevation of dopamine D2 receptors in schizophrenia is underestimated by radioactive raclopride. Arch Gen Psychiatry 1990;47:1170-1172.
31. 3H]raclopride to rat and human beam membranes. J Neurochem 1990,55:2048-2057.
32. 76Br]bromolisuride. In: Bunney WE, Hippius H, Laakmann G, Schmaub M, eds. Neuropsychopharmacology. New York, Springer-Verlag 1990,409-417
33. 3H]raclopride. Synapse 1989,3:96-97.
34. 3H]Raclopride J Neural Transm 1988,73 7-21.
35. 3H]raclopride Biochem Pharmacol 1985,34:225-229.
36. Pfeiffer A, Past A, Mehraien P, Herz A. Opiate receptor binding sites in human brain. Brain Res 1982;248.87-96
37. Rothman RB, Bykor V, Reid A, De Costa BR, Newman AH, Jacobson AE, Rice KC. A brief study of the selectivity of norinaltorphimine, (-)-cyclofoxy, and (+)-cyclofoxy among opiod receptor subtypes in vitro. Neuropeptides 1988;3.493-400.
38. Farde L, Wiesel FA, Stone-elander S, Halldin C, Nordstrom AL. Hall K, Sedvall G D2 dopamine receptors in neuroleptic-naive schizophrenic patients Arch Gen Psychiatry 1990;47:213-219
39. 3H]Ro 15-1788 binding to benzodiazepine receptors in human postmortem brain homogenates J Neurochem 1990;55:1310-1315.
40. 11C]raclopride. J Cereb Blood Flow Metab 1993;13:310-314.
41. 11C]diprenorphine and positron emission tomography. J Cereb Blood Flow Metab 1991;11:204-219.
42. d with the opiate antagonist cyclofoxy: equilibrium studies in the conscious rat J Cereb Blood Flow Metab 1991;11:529-544
43. 18F]-N-(p-Nuobenzil) spiperone in rats. Nucl Med Biol 1993;20:269-278
44. Tsai RS, Carrupt PA, Testa B, Gaillard P, El Tayar N Effects of solvation on the ionization and conformation of raclopride and other antidopaminergic 6-methoxysalicylamides insight into the pharmacophore. J Med Chem 1993;36:196-204.
45. 18F] labeled ligand with improved properties. J Cereb Blood Flow Metab 1991,11:S604.
46. 14C]iodoantipyrine. Am J Physiol 258,H1598-H1598